Booth Bruce 4/A

What Happened
Booth Bruce (listed as a Director) reported multiple sales of Kymera Therapeutics (KYMR) common stock on June 29, 2026. The filing shows aggregate disposals of 76,650 shares across several trades at reported weighted-average prices, generating roughly $8.28 million in proceeds. These transactions are coded as sales (S) — routine disposals rather than purchases or option exercises.

Key Details

• Filing date: July 2, 2026 (Amended Form 4). Period of report: June 26, 2026. Transactions dated June 29, 2026.
• Aggregate shares sold: 76,650; aggregate proceeds: ≈ $8,281,903.
• Reported prices: weighted-average prices per reported lot; overall trade prices ranged roughly from $105.02 to $111.63 per share (sales executed in multiple transactions).
• Relevant footnotes: sales were executed pursuant to a Rule 10b5-1 plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. (F1). The filing was amended to correct the allocation of reported sales between Atlas Venture Fund X and Atlas Venture Opportunity Fund I; the aggregate sold amount is unchanged. Reporting person disclaims Section 16 beneficial ownership of shares held by those funds except to the extent of any pecuniary interest (F11). The filing notes weighted-average pricing and offers to provide detailed breakdowns of trades/prices on request (F3, F5–F10).
• Shares owned after transaction: not specified in the summary data provided here (original filing had an inadvertent misreport which this amendment corrects — F2).
• Transaction code: S = Sale. This is an amendment to the original Form 4 (not a new late-report flag in the supplied data).

Context
These sales appear to be institutional dispositions by Atlas Venture-affiliated funds (Atlas Venture Fund X and Atlas Venture Opportunity Fund I) under a pre-established 10b5-1 plan rather than a personal, spontaneous trade by an individual executive. The reporting structure indicates the listed reporting person is a member of the general partner entities and disclaims direct Section 16 beneficial ownership of the funds’ holdings, except for any pecuniary interest. Institutional or planned sales are common and do not, by themselves, indicate management’s view on company fundamentals. For full details (exact post-sale holdings or the per-price breakdown of each sub-trade), consult the amended Form 4 filing (Accession: 0001451612-26-000022).